Physician profile
Aliya Saeed
NPI 1588808067
$1,819.51
in general payments reported to CMS, 2019-2025
25 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $175 · 2021: $327 · 2022: $213 · 2023: $182 · 2024: $319 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768 · Education: $57.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.59 |
| Education | $57.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $230.56 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $188.21 | 2019-2025 | Krystexxa, Parsabiv, Aranesp |
| Travere Therapeutics, INC. | $152.13 | 2021-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $139.63 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $129.98 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $114.19 | 2019-2024 | Velphoro |
| Mallinckrodt Hospital Products INC. | $100.54 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.53 | 2022-2025 | |
| Horizon Therapeutics Plc | $88.79 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $84.77 | 2021-2022 | |
| Ardelyx, INC. | $80.01 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $62.10 | 2019-2025 | Vafseo |
| Opko Pharmaceuticals, LLC | $59.35 | 2019-2020 | |
| Vifor Pharma, INC. | $58.09 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $46.01 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $28.14 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.43 | 2024 | Jardiance |
| Ani Pharmaceuticals, INC. | $22.89 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.03 | 2025 | Ultomiris |
| Genzyme Corporation | $20.93 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.71 | 2025 | Tryvio |
| Daiichi Sankyo INC. | $13.87 | 2021 | |
| Apellis Pharmaceuticals, INC. | $13.59 | 2025 | Empaveli |
| Arbor Pharmaceuticals, INC. | $11.91 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $10.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliya Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.